KG Bio (Kalbe)

Business focus

MedTech, BioTech & Pharma

Description

KG Bio is a clinical-stage biotech company established in 2016 as a joint venture between Southeast Asia's largest listed pharmaceutical company, Kalbe Farma, and South Korea's Genexine Inc. It licenses and commercializes novel oncology biologics outside the US, Western Europe and China; in October 2023 it received first market approval from Indonesia's BPOM regulator for its long-acting erythropoietin, Efepoetin alfa.